Sanofi raises outlook as quarterly Dupixent sales cross €5B for first time
NiveshIQ
NSE: SANOFI
Sanofi India Ltd.
₹3,366.30▼ ₹53.60 (-1.57%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on SANOFI. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Sanofi India Ltd.
Sanofi India Limited is a leading pharmaceutical company in India, providing a wide range of products across various therapeutic areas, including diabetes, cardiology, and infections. The company operates through independent distributors and exports its products to approximately 24 countries. Sanofi India's revenue primarily comes from the sale of its pharmaceutical products, with notable brands such as Lantus, Toujeo, and Clexane. In recent news, the company reported a 14% decline in Q4 FY26 net profit to ₹1.03 billion, with revenue dropping 12% YoY. Despite this, Sanofi Consumer Healthcare India witnessed a 36% jump in Q1 net profit to ₹68 crore, driven by the relaunch of a recalled product. The company's strong brand portfolio and presence in the Indian market position it well for growt
Financial Highlights
| Metric | FY25 | FY26 | FY27 |
|---|---|---|---|
| Revenue | ₹2,013 Cr +1.40% | ₹1,773 Cr -11.90% | ₹910.00 Cr -48.70% |
| EBITDA Margin | 24.39% | 19.39% | 29.53% |
| Net Profit | ₹413.00 Cr -24.90% | ₹309.80 Cr -25.00% | ₹186.10 Cr -39.90% |
| EPS | ₹179.70 | ₹134.56 | ₹80.81 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Sanofi Consumer Healthcare India Q1 Net Profit Rises To 688M Rupees Versus 607M YoY
Sanofi and Servier execs talk oncology: Pitches, Europe's position, and China's advantage
🔒
+ 3 more stories about Sanofi India Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹472 Cr, PAT ₹103 Cr, EPS ₹44.61, EBITDA margin 31.2%. Growth context: revenue QoQ +12.4%, PAT QoQ +66.9%. Street verdict: miss, revenue surprise -9.6%, PAT surprise -20.2%.
Growth & Expansion: We expect Sanofi to maintain its strong growth trajectory, driven by the ramp-up of its new product ...
Financial Outlook: Sanofi's financials are expected to improve in FY27, with consensus estimates indicating a 25% YoY in...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for SANOFI
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track SANOFI alongside your other holdings
Unlock full SANOFI research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Sanofi India Ltd.?
NiveshIQ detects active intelligence signals for Sanofi India Ltd. (SANOFI) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Sanofi India Ltd.?
Sanofi India Ltd. is listed on NSE/BSE with a market capitalisation of ₹775,279.8L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.